Immunomodulatory effects of IL-33 in atopic dermatitis
Brief description of study
The purpose of this study is to define the effects of neutralizing a certain protein affecting healthy and diseased skin and blood from patients with atopic dermatitis and to determine if the response to neutralization will differ between different subtypes of atopic dermatitis
Detailed description of study
The purpose of this study is to define the effects of neutralizing a certain protein (IL-33) affecting healthy and diseased skin and blood from patients with atopic dermatitis and to determine if the response to neutralization will differ between different subtypes of atopic dermatitis.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: healthy
-
Age: 18 years - 100 years
-
Gender: All
Inclusion Criteria
Active moderate to severe atopic dermatitis (AD) or healthy individuals who are similarly matched to enrolled AD patients in age, race, and sex
Exclusion Criteria
Systemic immunosuppressant in the past 6 months
Use of UVB or UVA phototherapies or tanning beds in the past 3 months
Use of topical steroids in/around biopsy sites >1 (preferably 2) week(s)
History of primary or secondary immunodeficiency disorders/diseases
History of keloid scar formation
History of allergy to lidocaine or other amide local anesthetics
History of bleeding disorders that could result in prolonged bleeding
History of prolonged or poor wound healing
Find a site
,
Send a message
Enter your contact details to connect with study team
Primary Contact
Interested in the study?
Select a study center that’s convenient for you, and get in touch with the study team.
Please choose between Voice or SMS based delivery of verification code
or